FIGURE 3 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment

Systemic injection of IL21-anti-HSA promoted tumor site–focused antitumor activities. A, Diagram of the experimental protocol. C57BL/6 mice were injected intraperitoneally with FTY720 the day before tumor inoculation, and injected every other day. The next day, mice were inoculated with MC38 colon adenocarcinoma cells subcutaneously, and 5 days later, IL21-anti-HSA was injected intraperitoneally. Treatments were given every 4 days for a total of four treatments. Mouse tumor growth curves (n = 4–5) were drawn. B, Mouse tumor growth curve. C–F, The tumor growth curve of a single mouse in the above different treatment groups. Data are presented as mean ± SEM, and two-way ANOVA test was used to compare statistical differences in tumor growth curves between different groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.